Lins Gel
PAIN RELEVE OINTMENT CONTAINS:Diclofenac 1 % W/W,Methyl Salicylate 10 % W/W,Menthol 5%W/W, Linseed Oil 3 %W/W,Benzyl Alcohol 1 % W/W Ointment
Nonprescription (over-the-counter) diclofenac(LINS GEL) topical gel is used to relieve pain from arthritis in certain joints such as those of the knees, ankles, feet, elbows, wrists, and hands. Prescription diclofenac topical solution (LINS GEL) is used to relieve osteoarthritis pain in the knees.
SIDE EFFECTS OF DICLOFENAC + LINSEED OIL + METHYL SALICYLATE (LINS GEL):
GI DISTURBANCES; HEADACHE, DIZZINESS, RASH; GI BLEEDING, PEPTIC ULCERATION; ABNORMALITIES OF KIDNEY FUNCTION. PAIN AND TISSUE DAMAGE AT INJ SITE (IM); LOCAL IRRITATION (RECTAL); TRANSIENT BURNING AND STINGING (OPHTHALMIC). POTENTIALLY FATAL: STEVENS-JOHNSON SYNDROME, EXFOLIATIVE DERMATITIS, TOXIC EPIDERMAL NECROLYSIS.
DRUG INTERACTIONS OF DICLOFENAC + LINSEED OIL + METHYL SALICYLATE (LINS GEL):
NOT TO BE GIVEN IV TO PATIENTS WHO ARE RECEIVING OTHER NSAIDS OR ANTICOAGULANTS INCLUDING LOW DOSE HEPARIN. RENAL FUNCTION MAY BE WORSENED WHEN USED WITH CICLOSPORIN OR TRIAMTERENE. ALTERED ABSORPTION WHEN GIVEN WITH SUCRALFATE, COLESTYRAMINE OR COLESTIPOL. OPHTHALMIC APPLICATION OF DICLOFENAC MAY REDUCE THE EFFICACY OF OPHTHALMIC ACETYLCHOLINE AND CARBACHOL. INCREASED RISK OF GI ULCERATION AND BLEEDING WHEN USED WITH CORTICOSTEROIDS, ASPIRIN OR ANTICOAGULANTS. POTENTIALLY FATAL: INCREASES BLOOD LEVELS OF DIGOXIN, LITHIUM AND METHOTREXATE. POTENTIATE POTASSIUM-SPARING DIURETICS.
CONTRAINDICATIONS OF DICLOFENAC + LINSEED OIL + METHYL SALICYLATE (LINS GEL):
ACTIVE PEPTIC ULCER; HYPERSENSITIVITY TO DICLOFENAC OR OTHER NSAIDS. TREATMENT OF PERIOPERATIVE PAIN IN CABG SURGERY. 3RD TRIMESTER OF PREGNANCY. TOPICAL: NOT TO BE APPLIED ONTO DAMAGED OR NONINTACT SKIN.
MECHANISM OF ACTION OF DICLOFENAC + LINSEED OIL + METHYL SALICYLATE (LINS GEL):
DICLOFENAC HAS POTENT ANTI-INFLAMMATORY, ANALGESIC AND ANTIPYRETIC ACTIONS. IT INHIBITS THE ENZYME, CYCLOOXYGENASE, THUS RESULTING IN REDUCED SYNTHESIS OF PROSTAGLANDIN PRECURSORS. ABSORPTION: RAPIDLY ABSORBED (ORAL SOLUTION, RECTAL SUPPOSITORY, IM); MORE SLOWLY (ENTERIC-COATED TAB). DISTRIBUTION: PENETRATES SYNOVIAL FLUID; ENTERS BREAST MILK (SMALL AMOUNTS). PROTEIN-BINDING: >99%. METABOLISM: EXTENSIVELY HEPATIC; CONVERTED TO METABOLITES. EXCRETION: ABOUT 60% EXCRETED IN URINE AS GLUCURONIDE AND SULFATE CONJUGATES; 35% IN BILE; 1-2 HR (ELIMINATION HALF-LIFE).
SPECIAL PRECAUTIONS FOR DICLOFENAC + LINSEED OIL + METHYL SALICYLATE (LINS GEL):
HISTORY OF GI ULCERATION; IMPAIRED CARDIAC, RENAL OR HEPATIC FUNCTION; HYPERTENSION; LACTATION. IV ADMIN IN PATIENTS WITH MODERATE OR SEVERE RENAL IMPAIRMENT; HYPOVOLAEMIA OR DEHYDRATION; ASTHMA, PORPHYRIA. MONITOR LFTS IN PATIENTS ON PROLONGED THERAPY. MAY PROLONG BLEEDING TIME; CAUTION WHEN USED IN PATIENTS WITH COAGULATION DISORDERS OR ON ANTICOAGULANTS. PROLONGED THERAPY MAY INCREASE RISK OF ANAEMIA. 1ST AND 2ND TRIMESTER OF PREGNANCY. ELDERLY, DEBILITATED PATIENTS.
